Details for Patent: 7,910,610

Title:	Methods of administering pirfenidone therapy
Abstract:	The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.
Inventor(s):	Bradford; Williamson Ziegler (Ross, CA), Szwarcberg; Javier (San Francisco, CA)
Assignee:	Intermune, Inc. (Brisbane, CA)
Filing Date:	Oct 08, 2010
Application Number:	12/901,245
Claims:	1. A method of administering pirfenidone therapy to a patient in need thereof, comprising administering to the patient a therapeutically effective amount of pirfenidone while avoiding co-administration of a strong cytochrome P450 1A2 (CYP1A2) inhibitor, wherein said patient is also in need of therapy with a strong CYP1A2 inhibitor. 2. The method of claim 1 wherein the patient has idiopathic pulmonary fibrosis (IPF). 3. The method of claim 1 wherein the therapeutically effective amount of pirfenidone is a daily dosage of 2400 mg or 2403 mg per day. 4. The method of claim 1 wherein 800 or 801 mg of pirfenidone is administered to the patient three times per day, with food. 5. A method of administering pirfenidone therapy to a patient in need thereof, comprising discontinuing administration of a strong CYP1A2 inhibitor to avoid an adverse drug interaction with pirfenidone, and administering to the patient a therapeutically effective amount of pirfenidone. 6. The method of claim 5 wherein the patient has idiopathic pulmonary fibrosis (IPF). 7. The method of claim 5 wherein the therapeutically effective amount of pirfenidone is a daily dosage of 2400 mg or 2403 mg per day. 8. The method of claim 5 wherein 800 or 801 mg of pirfenidone is administered to the patient three times per day, with food. 9. The method of claim 5 wherein the strong CYP1A2 inhibitor is discontinued within 1 month prior to starting pirfenidone therapy. 10. The method of claim 5 wherein the strong CYP1A2 inhibitor is discontinued within 2 weeks prior to starting pirfenidone therapy. 11. The method of claim 1 or 5 wherein the patient is advised that co-administration of pirfenidone with the strong CYP1A2 inhibitor can alter the therapeutic effect or adverse reaction profile of pirfenidone.